Aridis Pharmaceuticals Currently Presenting Webinar; ‘New Approaches To Treating Infections In Cystic Fibrosis Patients AR-501 Phase 2 Trial Update’; Shares Spike Lower
https://redchip.zoom.us/webinar/register/WN_WB4K1ES0S1aJzl5ucesN5A
Allogene Therapeutics Announces Publication In Nature Medicine Of Data From Its Phase 1 UNIVERSAL Study Of ALLO-715 For The Treatment Of Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that data from its Phase 1
Why Kura Oncology Stock Is Moving Higher Tuesday Morning
Kura Oncology Inc (NASDAQ: KURA) shares are trading higher Tuesday after the company announced the FDA clearance of its Inve
Altamira Therapeutics Provides Update On Clinical Trials With Bentrio; Interim Analysis Shows Superior Efficacy Of Bentrio In Seasonal Allergic Rhinitis
HAMILTON, BERMUDA , Jan. 24, 2023 (GLOBE NEWSWIRE) --
Interim analysis of Australian NASAR trial in seasonal allergic rhinitis shows statistically significant improvement with Bentrio® in nasal symptom primary
Catalyst Pharmaceuticals Comments On FDA’s Announcement Of Its Position On Orphan Drug Exclusivity In Light Of The 11th Circuit Decision In Catalyst Pharmaceuticals, Inc. v. Becerra
Announced Earlier Today-Notice Received from ANDA Filer for FIRDAPSE®
CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a
What’s Going On With Cadrenal Therapeutics Stock Today
The FDA has granted a Fast Track designation to Cadrenal Therapeutics Inc’s (NASDAQ:CVKD) tecarfarin for the prevention of systemic thromboembolism, more commonly…
COVID-19 Vaccine Strategy Might Follow The Influenza Shot Way, FDA To Decide Today
The FDA is considering a significant shift in the U.S.'s COVID-19 vaccine strategy to simplify vaccination against COVID-19.
Catalyst Pharmaceuticals Notified Of Abbreviated New Drug Application Filing For FIRDAPSE
Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare